Multiple Myeloma, Multiple Myeloma in Relapse
Conditions
Keywords
Multiple Myeloma, Relapsed Multiple Myeloma, Refractory Multiple Myeloma
Brief summary
Participant that has been diagnosed with Relapsed/ Refractory Multiple Myeloma and are currently participating in a clinical trial which is closing. This research study is studying Ulocuplumab as a possible treatment. It's an expanded access from NCT01359657
Detailed description
This research study is an Expanded Access Trial, which is a way to provide an investigational therapy to individuals who are not eligible to receive that therapy in a clinical trial, but have a serious or life-threatening illness for which other treatments are not available. The purpose of this expanded access program is to treat participants diagnosed with relapsed or refractory multiple myeloma with an investigational drug called ulocuplumab. Participants enrolled in the program will receive ulocuplumab with lenalidomide and dexamethasone or ulocuplumab with bortezomib and dexamethasone. Ulocuplumab is supposed to kill myeloma cells. Lenalidomide, which is also known as Revlimid® and Bortezomib, which is also known as Velcade®, are approved by the FDA for treatment of Multiple Myeloma. Dexamethasone, also known as Decadron®, is also approved by the FDA for other treatments. It is a type of steroid medication that fights inflammation.
Interventions
DRUGUlocuplumab
CXCR4 inhibitor given weekly on a 28 day cycle intravenously
DRUGLenalidomide
immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
DRUGBortezomib
proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
DRUGDexamethasone
steroid given at physician discretion on a 28 day cycles
Sponsors
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* Signed informed consent document * Must be currently participating on protocol 11-240 (DFCI)/ CA 212-002(BMS), tolerating therapy, and still receiving benefit from treatment.
Exclusion criteria
* Prior exposure to Ulocuplumab other than in DFCI Protocol 11-240 (BMS protocol CA212-002) or any other any other CXCR4 inhibitor (small molecule within 14 days; antibody against CXCR4 within 10 weeks).
Countries
United States
Outcome results
None listed